CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
NKTR-255 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04616196
NCT04616196Phase 2Completed
CompareCT.gov

A Phase 1b/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-255 Monotherapy or in Combination With Cetuximab as a Salvage Regimen for Solid Tumors

Nektar Therapeutics·interventional·Posted Nov 4, 2020·Updated Jun 8, 2025

In Brief

A Phase 2 clinical trial evaluating NKTR-255 and Cetuximab for Head and Neck Squamous Cell Carcinoma and Colorectal Cancer. Completed, enrolled 25 participants across 6 sites.

Detailed Summary

This is a Phase 1b/2, open-label multicenter study evaluating NKTR-255 as a monotherapy and together with cetuximab in patients with head and neck squamous cell carcinoma (HNSCC) and colorectal carcinoma (CRC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHead and Neck Squamous Cell Carcinoma, Colorectal Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedNov 4, 2020
Enrollment StartOct 30, 2020
Primary CompletionMar 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.7 years ago

Interventions

NKTR-255drug

NKTR-255 IV every 21 days

Cetuximabdrug

Cetuximab will be given at specified doses on specified days